SARC024: A blanket protocol to study oral regorafenib in patients with selected sarcoma subtypes
The purpose of this study is to compare the effects good and/or bad of the study drug, regorafenib, versus placebo on your liposarcoma or bone sarcoma. Another purpose is to study the effects of the study drug on your Ewing-sarcoma to determine the effects, good and/or bad.
Liposarcoma, Osteogenic sarcoma (bone sarcoma), Ewing / Ewing- like sarcoma and Rhabdomyosarcoma.
Participants 18 and older with liposarcoma, bone sarcoma, or Ewing sarcoma who have had at least one prior form of systemic treatment for their cancer. Participants 5 or older with Rhabdomyosarcoma. Screening labs and imaging studies will be done to confirm eligibility.
5 - 120
Healthy Volunteers Needed
Duration of Participation
Participants will be in the study for as long as they are seeing clinical benefit.
Sarcoma Alliance for Research through Collaboration (SARC)